200 related articles for article (PubMed ID: 10151730)
1. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
[TBL] [Abstract][Full Text] [Related]
2. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
[TBL] [Abstract][Full Text] [Related]
3. Pegaspargase: an alternative?
Holle LM
Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
[TBL] [Abstract][Full Text] [Related]
4. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
[TBL] [Abstract][Full Text] [Related]
5. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
6. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
8. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
9. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
10. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
11. Pegaspargase.
Alfieri DR
Pediatr Nurs; 1995; 21(5):471-4, 490. PubMed ID: 8684851
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of asparaginase activity levels following treatment with pegaspargase.
Bleyer A; Asselin BL; Koontz SE; Hunger SP
Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
[TBL] [Abstract][Full Text] [Related]
13. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
16. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R
Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472
[No Abstract] [Full Text] [Related]
17. Pegaspargase for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 1995 Mar; 37(944):23-4. PubMed ID: 7877556
[No Abstract] [Full Text] [Related]
18. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
Douer D; Yampolsky H; Cohen LJ; Watkins K; Levine AM; Periclou AP; Avramis VI
Blood; 2007 Apr; 109(7):2744-50. PubMed ID: 17132721
[TBL] [Abstract][Full Text] [Related]
19. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
20. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
Shinnick SE; Browning ML; Koontz SE
J Pediatr Oncol Nurs; 2013; 30(2):63-77. PubMed ID: 23380527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
